Source - RNS
RNS Number : 4927K
Silence Therapeutics PLC
22 September 2016

22 September 2016


Notice of Results


London, 22 September 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results for the six months ending 30 June 2016 on Tuesday 27 September 2016.  


Silence Therapeutics plc

Tel: +44 (0)20 3457 6900

Ali Mortazavi, Chief Executive Officer

David Ellam, Chief Financial Officer

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Tel: +44 (0)20 7523 8350

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Peel Hunt LLP (Joint Broker)

Tel: +44 (0)20 7418 8900

James Steel/Oliver Jackson

Media Enquiries:

Tel: +44 (0) 20 3727 1000

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert



Notes to Editors


About Silence Therapeutics plc


Our technology harnesses the body's natural mechanisms to create therapeutic effects within its cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, as well as advanced chemistries to enhance the effective delivery of therapeutic RNA molecules to target cells.

This information is provided by RNS
The company news service from the London Stock Exchange